Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Replication-defective bovine adenovirus type 3 as an expression vector.

P S Reddy1, N Idamakanti, Y Chen

  • 1Virology Group, Veterinary Infectious Disease Organization, University of Saskatchewan, Saskatoon, Saskatchewan, Canada S7N 5E3.

Journal of Virology
|October 9, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Natural and inducible regulatory B cells are widely distributed in ovine lymphoid tissues.

Veterinary immunology and immunopathology·2019
Same author

Evidence for the existence of regulatory and effector B cell populations in Peyer's patches of sheep.

Veterinary immunology and immunopathology·2016
Same author

Review: Capripoxvirus Diseases: Current Status and Opportunities for Control.

Transboundary and emerging diseases·2015
Same author

Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles.

Vaccine·2012
Same author

Complementation cell lines for viral vectors to be used in gene therapy.

Cytotechnology·2012
Same author

Veterinary DNA vaccines.

Methods in molecular medicine·2011
Same journal

Alpha-herpesvirus UL55 synergizes with ICP27 to suppress type I interferon production through conserved and host-adapted mechanisms.

Journal of virology·2026
Same journal

Maintenance of Hokkaido virus, a genotype of <i>Orthohantavirus puumalaense</i>, in the rodent host <i>Myodes rufocanus bedfordiae</i> under natural conditions.

Journal of virology·2026
Same journal

Neurotropism and interferon-dominated immune responses in a mouse-adapted coxsackievirus A16 infection model.

Journal of virology·2026
Same journal

Oropouche virus causes acute hepatitis in mice controlled by type I interferons.

Journal of virology·2026
Same journal

Hybrid extrachromosomal DNA in HPV-driven cancers.

Journal of virology·2026
Same journal

Sequence heterogeneity in pneumonia virus of mice reveals G gene-dependent modulation of virulence.

Journal of virology·2026
See all related articles

Researchers developed a replication-defective bovine adenovirus type 3 (BAV-3) vector for gene therapy and vaccination. This novel BAV-3 vector shows promise for prolonged expression and reduced toxicity in animal studies.

Area of Science:

  • * Virology
  • * Gene Therapy
  • * Vaccinology

Background:

  • * Recombinant human adenovirus (HAV)-based vectors are used in gene therapy and vaccination.
  • * There is a need for alternative vectors with improved expression duration and reduced toxicity.
  • * Bovine adenovirus type 3 (BAV-3) presents a potential alternative vector system.

Purpose of the Study:

  • * To develop a replication-defective BAV-3 vector for gene therapy and vaccination.
  • * To create and characterize bovine cell lines that complement BAV-3 E1A deletions.
  • * To evaluate the potential of BAV-3 as a vector for cattle diseases and human gene therapy.

Main Methods:

  • * Construction of replication-defective BAV-3 by deleting E1A and E3 regions.
  • * Development of bovine cell lines (VIDO R2 and 6.93.9) to complement BAV-3.

Related Experiment Videos

  • * Generation of recombinant BAV-3 vectors expressing foreign genes (bovine herpesvirus type 1 glycoprotein D, bovine coronavirus hemagglutinin-esterase).

    • Main Results:

    • * Replication-defective BAV-3 vectors were successfully generated and grown in complementing cell lines.
    • * The E1A region of human adenovirus type 5 (HAV-5) can complement BAV-3 E1A deletions.
    • * Recombinant BAV-3 vectors demonstrated suitability for animal studies on safety, gene expression, and immunogenicity.

    Conclusions:

    • * Development of E1A-complementing bovine cell lines and replication-defective BAV-3 vectors is a significant advancement.
    • * BAV-3 vectors hold potential for vaccination against cattle diseases and somatic gene therapy in humans.
    • * Further animal studies are warranted to fully define the safety and efficacy of BAV-3 vectors.